Photodynamic therapy using TLD-1433 represents a viable treatment option for BCG-unresponsive NMIBC CIS ... It is an operative procedure so it will be appealing to the urological community ...

Following surgery to remove the tumor, bladder cancer patients are typically given a live Bacillus Calmette Guerin (BCG) inoculation ... Joost Boormans, Professor of Urology at the Erasmus ...

The CISTO study is the only going prospective study comparing radical cystectomy vs bladder-sparing options for high-grade NMIBC.

Johnson & Johnson (J&J) has reported more data supporting the efficacy of its intravesical drug release system TAR-200 in ...

doxorubicin or pirarubicin), whether immediately after surgery or after 2 weeks' delay, had similar outcomes to those who did not. By contrast, the 35 patients who received intravesical BCG ...

uGDB, utilizing next-generation sequencing to detect bladder cancer-associated mutations and DNA alterations, has previously shown associations with recurrence and therapy response.

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...

Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates of surgery avoidance and ... Chamie is an ...

Joseph Jacob, MD, discusses data from the phase 2b SunRISe-1 study, cohort 2, evaluating TAR-200 in BCG-unresponsive high-risk NMIBC with carcinoma in situ.

1 Despite advancements, standard treatment has remained largely unchanged for over 40 years, leaving patients with limited treatment options if initial BCG therapy does not work.2 TAR-200 delivers ...